NCT00002118已完成不适用
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 600
- 试验地点
- 2
研究概览
简要总结
To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT), or who have completed other ddC protocols, or who are ineligible for ongoing clinical trials.
详细描述
Patients receive ddC and are evaluated at study entry and every 3 months thereafter, until 3 months after ddC becomes approved for pediatric patients or the sponsor deems it necessary to terminate the protocol.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With EpilepsyEpilepsyNCT00938912UCB BIOSCIENCES, Inc.366
Unknown
1 期
Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic DermatitisAtopic DermatitisNCT03415282Dermavant Sciences GmbH24
终止
3 期
Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain PatientsChronic PainNCT02321319Mallinckrodt5
终止
2 期
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled TrialDown SyndromeNCT00675025Eisai Inc.117
已完成
2 期
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic DisordersBipolar DisorderSchizoaffective DisorderSchizophreniaNCT00650611Pfizer's Upjohn has merged with Mylan to form Viatris Inc.63